OS Therapies Incorporated (OSTX)
Automate Your Wheel Strategy on OSTX
With Tiblio's Option Bot, you can configure your own wheel strategy including OSTX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol OSTX
- Rev/Share 0.0
- Book/Share 0.1968
- PB 9.6777
- Debt/Equity 0.0
- CurrentRatio 1.0277
- ROIC -731.0867
- MktCap 60657212.0
- FreeCF/Share -0.4789
- PFCF -5.043
- PE -0.0123
- Debt/Assets 0.0
- DivYield 0
- ROE -2746.3699
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | OSTX | Lake Street | -- | Buy | -- | $19 | April 2, 2025 |
News
OS Therapies Announces Overall and Event Free Survival Key Subgroup Data for OST-HER2 in Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
Published: October 22, 2025 by: Newsfile Corp
Sentiment: Neutral
New York, New York--(Newsfile Corp. - October 22, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced additional overall and event free survival data generated from the Company's 41-patient Phase 2b clinical trial of its off-the-shelf immunotherapeutic candidate OST-HER2 in recurrent, fully resected, pulmonary metastatic osteosarcoma (the "Phase 2b Osteosarcoma Trial"). The Company previously announced statistically significant positive final 2-year overall survival data from its Phase 2b Osteosarcoma Trial on October 10, 2025.
Read More
OS Therapies Granted Final Type C Meeting by U.S. FDA and pre-MAA Meeting by U.K. MHRA for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
Published: October 17, 2025 by: Newsfile Corp
Sentiment: Neutral
Final FDA Type C Meeting December 11, 2025 - biomarker data to be available October 10, 2025 FDA/Osteosarcoma Institute Workshop narrows focus for OST-HER2 overall survival, biomarker correlation & canine osteosarcoma data New York, New York--(Newsfile Corp. - October 17, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced that the United States Food & Drug Administration ("FDA") has granted a second Type C Meeting, following its successful End of Phase 2 Meeting. The primary purpose of the meeting is to gain alignment on …
Read More
OS Therapies to Participate in Fall 2025 Conferences and Events
Published: October 07, 2025 by: Newsfile Corp
Sentiment: Neutral
Daytime Emmy Awards participation - 2 nomination for 'Shelter Me: Cancer Pioneers' Comparative Oncology documentary that features clinicians, veterinarians and human & canine patients who participated in OST-HER2 clinical trials New York, New York--(Newsfile Corp. - October 7, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced its participation in upcoming October 2025 conferences and events. Cell and Gene Meeting on the Mesa What: Partnering and one-on-one meetingsWhen: October 6-8, 2025Where: Arizona Biltmore, Phoenix, AZWho: Paul Romness, Chairman & CEOHow: OS Therapies is now …
Read More
OS Therapies Provides OST-HER2 UK MHRA and US FDA Osteosarcoma Regulatory Update
Published: September 30, 2025 by: Newsfile Corp
Sentiment: Neutral
Company updates sequence of OST-HER2 regulatory submissions, prioritizing UK MHRA conditional Marketing Authorisation Application (MAA) submission following positive August 2025 Scientific Advice Meeting feedback from UK MHRA In principle, UK MHRA accepts use of historical control arm to support conditional MAA UK MHRA conditional MAA and US FDA Biologics Licensing Application (BLA) submissions expected to be completed within 30 days of each other, between December 2025 and January 2026 Company to propose use of immune activation biomarker coupled with overall survival data as surrogate efficacy endpoint to support Accelerated Approval in Type C Meeting invited by FDA, following positive End …
Read More
OS Therapies Closes $4.2 Million in Warrant Exercise Inducement and Exchange Offer
Published: July 14, 2025 by: Newsfile Corp
Sentiment: Neutral
Cash runway extended through 2026, beyond September 30, 2026 sunset date for rare pediatric priority review voucher (PRV) program Additional funding allows Company to advance strategic alternatives for OS Animal Health, close out OST-504 (previously ADXS-504) prostate cancer study and initiate AI-driven next-gen tADC product candidate modeling New York, New York--(Newsfile Corp. - July 14, 2025) - OS Therapies (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that it has closed its previously announced warrant exercise inducement and exchange offer. The Company raised a total of $4.2 million …
Read More
OS Therapies Reports First Quarter 2025 Financial Results and Provides Business Update
Published: May 16, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--OS Therapies Inc. (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today reported first quarter 2025 financial results ended March 31, 2025 and provided a business update. “The first quarter of 2025 was a crucial execution quarter for OS Therapies, as we announced positive data from our OST-HER2 Phase 2b clinical trial in the prevention of recurrent, fully resected, lung metastat.
Read More
OS Therapies Announces Issuance of U.S. Patent #12,239,738 Protecting Commercial Manufacturing Market Exclusivity for OST-HER2 in Rare Pediatric Cancer Osteosarcoma and Full Listeria Cancer Immunotherapy Platform into 2040
Published: May 07, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced the issuance of United States Patent #12,230,738 protecting proprietary commercial manufacturing methods for the Company's listeria monocytogenes (Lm) cancer immunotherapy platform technology into 2040. The Company is seeking to gain FDA approval for lead asset OST-HER2 in the treatment of pediatric.
Read More
OS Therapies FDA Meeting Request Granted
Published: April 22, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that the US Food & Drug Administration (“FDA”) granted the Company's meeting request to gain alignment on the surrogate endpoint to support Breakthrough Therapy Designation & Accelerated Approval of OST-HER2 in the Prevention of Recurrence of Fully Resected, Lung Metastatic Osteosarcoma. FDA.
Read More
OS Therapies' OST-HER2 Immunotherapy for Osteosarcoma Featured in Upcoming Movie Shelter Me: The Cancer Pioneers
Published: March 25, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that OST-HER2 is featured in the upcoming movie Shelter Me: The Cancer Pioneers. The movie offers a look into canine comparative oncology, a field that compares treatment of cancers in dogs to those in people, and covers developing treatments for rare forms of cancer. OST-HER2 is an immunotherapy for.
Read More
Calidi Biotherapeutics and OS Therapies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Published: February 28, 2025 by: Accesswire
Sentiment: Neutral
ORLANDO, FLORIDA / ACCESS Newswire / February 28, 2025 / RedChip Companies will air interviews with Calidi Biotherapeutics, Inc. (NYSE American:CLDI) and OS Therapies Inc. (NYSE American:OSTX) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV this Saturday, March 1, at 7 p.m. Eastern Time (ET).
Read More
About OS Therapies Incorporated (OSTX)
- IPO Date 2024-08-01
- Website https://ostherapies.com
- Industry Biotechnology
- CEO Paul A. Romness
- Employees 4